The supervisory board of private joint-stock company Biofarma (Kyiv) on October 21, 2015 decided to close a company representative office in Belarus due to the restructuring of the company.
The company said that Biofarma fulfilled presentation functions in Belarus and was not involved in commercial operations.
As reported, on October 15, 2015, the supervisory board of Biofarma decided to close its representative office in Kazakhstan.
Biofarma is among the ten largest Ukrainian drug manufactures. Biofarma produces more than 20 immunobiological preparations of blood, as well as drugs obtained by recombinant DNA technology and probiotics.
Advertising
Advertising
MORE ABOUT
STADA to Become a Major Pharma Player in Ukraine by Acquiring Biopharma’s Pharmaceutical Prescription and Consumer Health Business
10:01, 02.12.2019
Govt permits Biofarma Plasma to export blood preparations in 2018
17:13, 02.01.2018
Biofarma could open blood plasma fractionator plant in July 2018
11:50, 15.12.2017
Biofarma Plazma receives heat production license
16:38, 21.11.2017
Biofarma to seek review of UNDP decision on outcome of tender for blood purchases
17:51, 19.05.2017
LATEST
DIM company accredits houses under construction in eOselia program
19:22, 02.05.2024
Shareholders of Interpipe Nyzhniodniprovsky Pipe Rolling Plant updates composition of supervisory board, re-elected four members for new term, incl its head
19:05, 02.05.2024
Philip Morris to invest $11 mln in launch, commercialization of new version of tobacco heating device in Ukraine
18:24, 02.05.2024
Number of transfers via NovaPay up by 18%, transactions by 24% in Q1 2024
19:32, 01.05.2024
McDonald's plans to expand partnership projects with filling stations